Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGT-53 with Irradiation and Chemotherapy in Pediatric Recurrent/Progressive CNS Malignancies
NCT03554707Phase 1Withdrawn
- Sponsor
- SynerGene Therapeutics, Inc.
- Start
- Jun 2022
- Primary completion
- Jun 2022
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SGT-53 in central nervous system tumor, sponsored by SynerGene Therapeutics, Inc. Primary endpoint: Incidence of Adverse Events at 13 months. Planned start Jun 2022; status: withdrawn.
02
Drugs
SGT-53
03
Conditions
central nervous system tumor
Beyond the preview
Go deeper on NCT03554707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03554707.